In Brief: Pharmacia & Upjohn's Estring
Pharmacia & Upjohn's Estring: Estradiol vaginal ring for treatment of local symptoms of urogenital atrophy is approved April 26. Estring had been "approvable" at FDA since Sept. 29. The product is an elastomer ring containing 2 mg of 17-beta estradiol that is inserted into the upper vagina, where it releases 50%-60% of the estradiol over a period of three months. Estring is the only product that treats both vaginal and urogenital symptoms of urogenital atrophy. The company plans to introduce Estring sometime this autumn...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth